PAMA reporting: guides and reference
Seven articles on PAMA private payor rate reporting: who is tested, who files, what the caps do to CLFS rates, and what the public data can and cannot answer.
PAMAwatch is a free PAMA reporting exposure checker for independent clinical labs. These guides are its written reference for the PAMA rule behind it.
PAMA Exposure Checker vs Manual CMS Lookup
A free automated PAMA exposure checker and a manual CMS data lookup start from the same public file and hit the same wall. What each method costs you in time.
Quadax PAMA Reporting Alternative
Quadax sells a guided, paid PAMA reporting service. pamawatch is a free first check of the $12,500 low expenditure floor, before any sales call.
Why nobody can hand you the list of applicable laboratories
1,729 independent labs billed Medicare CLFS above $12,500 in CY2024. That is one of PAMA’s two tests. The other cannot be computed from any public file.
How to determine your PAMA status from your own records
Both PAMA tests run on numbers only your own remittance data holds. The exact steps, with the regulation text and CMS’s own worked method beside each one.
The NPI takes the test, the TIN files the report
PAMA status is tested at the billing NPI, but the report is filed once per TIN and signed by an officer. Who does what, from the regulation and CMS’s FAQ.
PAMA 2026 cycle: every date, figure, and source
Collection and reporting dates, revenue thresholds, phase-in caps, and penalty amounts for the 2026 PAMA cycle, each row carrying its primary source.
The PAMA window closed July 31, 2026. What now?
The 2026 reporting period has ended. The penalty text as written, the adjusted dollar amounts, what CMS’s pages do not publish, and the 2029 cycle.
Two federal lab registries, and what each cannot see
CMS’s CLIA facility file and its Medicare billing file both describe clinical labs. A name and state join returned 0 of 60. What each can and cannot answer.
What PAMA reporting does to your CLFS rates
Reported private payor rates become the CLFS through a weighted median. The caps: no reduction in 2026, at most 15 percent a year for 2027 through 2029.